Benefits and risks of mitomycin use in the traumatized tracheal mucosa

Otolaryngol Head Neck Surg. 2007 Mar;136(3):459-63. doi: 10.1016/j.otohns.2006.09.012.

Abstract

Objective: To investigate the efficacy and early complications of mitomycin C (MMC) in tracheal wound models.

Study design and setting: Rabbits (N = 60) were randomized to undergo mucosal injuries to the upper and lower trachea including anterior 120 degrees full thickness (group A, n = 20), anterior 120 degrees partial thickness (group B, 20), and circumferential partial thickness (group C, 20). In each rabbit, the wounds were separately treated with MMC 1.0 mg/mL or saline, and the animals were sacrificed after three weeks.

Results: Twenty-seven of the 60 animals experienced early death because of tracheal rupture or airway obstruction caused by unresolved scabs on the preinjured tracheal mucosa; the incidence of early death was higher in groups A and C than in group B. In each group, the degree of tracheal stenosis was comparable in wounds treated with MMC and saline.

Conclusion: These findings suggest that topical MMC has no benefit when used to prevent tracheal stenosis. Acute airway obstruction may occur in MMC-treated rabbits with tracheal wounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Airway Obstruction / etiology
  • Animals
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / therapeutic use*
  • Cause of Death
  • Cicatrix / etiology
  • Disease Models, Animal
  • Female
  • Mitomycin / adverse effects
  • Mitomycin / therapeutic use*
  • Necrosis
  • Rabbits
  • Random Allocation
  • Respiratory Mucosa / injuries*
  • Respiratory Mucosa / surgery
  • Risk Assessment
  • Rupture, Spontaneous
  • Suture Techniques
  • Trachea / injuries*
  • Trachea / surgery
  • Tracheal Stenosis / etiology

Substances

  • Antibiotics, Antineoplastic
  • Mitomycin